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ABSTRACT : The risk factors of recurrence following surgical treatment for patients 
with breast cancer were clinically evaluated on the basis of a result of clinical analysis. 
   In this study, it is emphasized that special attention should focus on tissue CEA and 
DNA analysis. In conclusion, clinical uses of tissue positive CEA and aneuploid pattern 
in analysis of nuclear DNA content in cancer cells are of great value to forecast recurrence.
       INTRODUCTION 
 Progression of breast cancer completes a 
distant metastastasis to the lung and the liver 
in 70% of patients and 50% of bone metastasis. 
As the symptomes are complex, so it is difficult 
to care for these patients. 
 In this study, the risk factors for recurrence 
of breast cancer was clinically assessed in the 
analysis of clinical experience with 43 patients 
with recurrence of breast cancer. 
 In fact, recurrence of breast cancer commonly 
occurred as being local and distant metastasis. 
It is well known that distant metastases are seen 
in the bone, the lung, the liver and the brain. 
On the other hand, local metastasis is composed 
of local recurrence of the thoracic wall and bulky 
node metastasis in the neighboring nodes. 
 The purpose of this study is to certify the risk 
factor for recurrence of breast cancer in the 
clinical analysis of 43 patients with recurrence 
and to prevent recurrence of breast cancer fol-
lowing surgery.
        PATIENTS 
Table 1 showed reucrrent organs in patients
with breast cancer. The most predominant sites 
were the lung and the skin, followed by the bone, 
the lymphnodes, the liver and the pleura. 
 It implies that the lung and the liver which 
receives a large amount of blood is a favarable 
site for recurrence. Recurrence of local skin 
should be avoided by meticulous surgical tech-
nique, which prevent tumor cells implanta-
tion during surgical manipulation. 
 The time durations from surgery to clinical 
appearance of metastasis were shown in Table 
2. These ranged from one month to 99 months 
with varying variety of the time interval. The 
short time duration was shown in patients with 
pleural involvement and the long time duration 
was seen in patients with lung metastasis. 
 According to trim classification, there were 
no certain patterns to provoke recurrence as 
shown in Table 3. The disease stages in patients 
with reucrrence uniformly distributed in terms 
of tnm classification. It was interest to say 
that the recurrence more often occurred in 
patients with stage I or II disease of breast 
cancer. 
 The operative procedures used for primary 
breast cancer were listed in Table 4. Each 
procedure ensured oncologic radicality as for as 
possible, including combined operation with







lymph node 9 
local skin 14 
      including doubles of involved organs
             Tacle 2. 
location duration (average) 
lung 2-99(36.1) 
pleura 2-31(14.0) 
bone 10-57 (24.8) 
liver 1-57(27.8) 
lymph node 7-99(31.9) 
local skin 1-99(22.1) 
                             (month)
           Tacle 4. CEA stain 
 CEA stain cases % 
     - 14 (25.9) 
    ± 4 (7.4) 
    + 10 (18.5) 
    --+ 14 (25.9) 
    4w 12 (22.2) 
   Total 54 
              Ploidy
Ploidy case ( %) 
euploidy 18 (30.0) 
aneuploidy 42 (70.0) 
1.1 <Dl<1.5 13 (21.7) 
1.5 < Dl < 2.0 21 (35.0) 
2.0 < Dl 8 (13.3)







 n1a 7 
nl/3 12 
 n2 7 
 n3 3 
 stage I 14 
      11 12
      III 11
      IV 5
          Table 5. Serum CEA 
 Serum CEA cases (recurrene rate) 
 Positive 11(44) 
 normal 14(56) 
 Total 25 
                      positive : over 4ng/ml 
            CEA Stain 
Staning rate case ( %) 
     0% - 1 (3.7)
  -20% + 17 (63.0) 
   -50% +f- 6 (22.2) 
  80%- 3 (11.1) 
  Total 27
                          Table 6. 
 operaive procedure cases recurrence and rates** 
 extended radical mastectomy 29* (29/119=24.3) 
 standard mastectomy 8 ( 8/ 83= 9.6) 
 super-extende radical mastectomy 2 ( 2/ 7=28.6) 
 limited operation 4 ( 4/134= 3.0) 
**
oophrectomy in three patients. The highest 
recurrent rate was seen in super-and extend-
ed radical mastectomy. Recurrence was more 
likely to occur in patients who undergo ex-
tended-radical mastectomy because these proce-
dures were selected for relatively advanced 
cancer patients. 
 The serum CEA levels and a presence of 
tissuse CEA by staining were shown in Table 
5. The suggestion is made that high serum CEA 
level should not indicate an appearance of 
recurrence following surgical treatment for 
breast cancer. On the contrary, it is suggeted 
that high tissuse CEA enables us to know high 
possibility to recur. 
 Table 6 showed a result of an analysis of 
ploidy patterns in cancer cells accroding to the 
method by Schutte". The recurrent rate from 
cancer cells with aneuploidy was 30 percent 
although that from aneuploidy was 70 per cent. 
The highest recurrent rate was shown in 
aneuploidy in which DI ranged from 1.5 to 2.0.
         DISCUSSION 
 In this study, it is clinically evaluated as to 
whether recurrence of breast cancer could be 
predicted or not on the basis of the clinical 
analysis of patients with recurrence. 
 The predominant recurrent sites are the lung, 
the local skin and the lymph nodes. However, 
the disease stages in patients with reucrrence 
were uniformly distributed, not in one-side of 
the disease stage. 
 There was a tendency toward occurring 
recurrence in patients who underwent extended 
radical mastectomy. 
 It is a reflestion that these procedures are 
selected for advanced breat cancer patients. 
The suggestion was made that high tissue CEA 
content imply high possibility to recur although 
the serum CEA levels varied. 
 Black" 3' and Fischer4' reported that cellular 
atypisms are divided the five stages according 
to the irregularity, the sizes, the shapes, the 
staining of nuclei, nucleous and its division. 
Prognostic factors also have been evaluated in 
association with histologic findings. 
 However, objectively histologic finding is man-
datory for precise assessment of their prog-
noses. 
 Recently advances in flow cytometric tech-
niques enabled physicians to objectively assess 
the intensity of clinical malignancy in tumor 
cells". 
 Nishie' pointed out that ER positive breast 
cancers tended to demonstrate the lower DI 
and RI values. It seems that this fact reflects 
a hormone-dependent tumors of breast cancer. 
It is emphasized that assessment of biologic 
patterns in breast cancers helps determine the 
validity of chemoendocrine therapy in follow-up 
courses. 
 On the other hand, the serum CEA levels are 
now utilized widely as a clinical marker. 
 In case of breast cancer, serum CEA is too 
low to be useful for screening. It, however, is 
accepted that high serum CEA levels help us 
forecast recurrence and special attention focus-
ed on serum CEA as a prognostic factors`' 8' and 
the evaluation of therapeutic efficacy". 
 In this series, the serum CEA level failed to 
closely correlate with forecasting recurrence. 
On the other hand, tissue CEA level by staining 
in cancer tissuses correlated with recurrence as 
an index of in cancer tissues correlated with 
recurrence as an index of prognosis. It is well 
known that the prognosis of CEA-negative 
tumors is better than CEA-positive one10'. 
 In breast cancer, the clinical value of tissue-
CEA is still controversial, with some reports of 
a poorer prongnosis in CEA positive patients"' 
and others of not showing prognostic correla-
tion"). In this study, there was a certain prog-
nostic correlation between tissue CEA and 
recurrence. It seems reasonable to emphasize 
that CEA producition is an intrinsic biological 
characteristic of the tumor. 
 Kuhajda13' reproted that CEA-positive tumors 
are more likely to show metastasis, particularly 
severe metastasis. It is certain that tissue CEA-
positive tumors show a biologically malignant 
behavior to present local and distant metas-
tases and recur in early stage following surgery. 
Tissue CEA was positive in 96.3% of patients 
with recurrence, in contarst, high serum CEA 
was positive in 44% of them in this series. 
 The expression of tissue CEA is associated 
with a high incidence of recurrence in anticipa-
tion of a poor outcome.
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